



Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report

Chunguang Wang¹ · Shu Chen² · Qianru He^{2,3,4} · Tingting Sun^{2,3,4} · Peiran Xu¹

Received: 27 July 2022 / Accepted: 8 August 2022 / Published online: 16 August 2022
© Springer Science+Business Media, LLC, part of Springer Nature 2022

Correction to: Investigational New Drugs
<https://doi.org/10.1007/s10637-022-01262-2>

The figure images and its legends were missing on the online published paper.

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10637-022-01262-2>.

✉ Peiran Xu
peiranxu8888@163.com

¹ Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, China

² The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China

³ Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China

⁴ The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China